Among its strengths is its status as the largest study to date that focuses on the association between GLP-1 RA usage and the risk of psychiatric outcomes in real-world scenarios
While its still in research, its early data offers hope for patients struggling with obesity, diabetes, and metabolic dysfunction
WADA Prohibition The World Anti-Doping Agency classifies multiple components as prohibited substances: BPC-157: Listed under Section S0 (Non-Approved Substances), prohibited at all times TB-500: Listed under S2: Peptide Hormones, Growth Factors, prohibited at all times GHK-Cu: Not specifically prohibited but peptide combinations generally scrutinized KPV: Not explicitly listed but could fall under similar chemical structure provisions No Therapeutic Use Exemptions (TUEs) available for any prohibited components Combined formulations would fall under multiple prohibited categories Detection methods developed for BPC-157 (up to 4 days) and TB-500 WADAs prohibition reflects the lack of regulatory approval from health authorities worldwide for these peptides and concerns about tissue-regenerative and performance-enhancing properties
Physician review within hours
For those on GLP-1 medications, a regimen including creatine, weight training, and protein can be effective
